NF2 deletion	Malignant Pleural Mesothelioma	NF2 deletion	Malignant Pleural Mesothelioma	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B
NF2 deletion	Melanoma	NF2 deletion	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
NF2 K159fs*16	Breast Cancer	NF2 K159fs*16	Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
NF2 mutation	Breast Cancer	NF2 mutation	Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
NF2 mutation	Thyroid Gland Anaplastic Carcinoma	NF2 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
NF2 mutation	Renal Cell Carcinoma	NF2 mutation	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3
NF2 mutation	Meningioma	NF2 mutation	Meningioma	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3
NF2 mutation	Kidney Medullary Carcinoma	NF2 mutation	Kidney Medullary Carcinoma	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies cisplatin + carboplatin + pemetrexed + mitomycin Resistant : C4	cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies cisplatin + carboplatin + pemetrexed + mitomycin Resistant : C4

NF2 (Neurofibromin 2)

Associations(17)

Associations
(17)